CoChat

Dapiglutide, a novel dual GLP‐1 and GLP‐2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel

Open access
Reiner, Johannes, Berlin, Peggy, Held, Jascha, Thiery, Johanna, Skarbaliene, Jolanta, Griffin, Jonathan, Russell, Wayne, Eriksson, Per‐Olof, Berner‐Hansen, Mark, Ehlers, Luise, Vollmar, Brigitte, Jaster, Robert, Witte, Maria, Lamprecht, Georg · 2022 · Journal of Parenteral and Enteral Nutrition
Cited by 43

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Background: Extensive intestinal resection may lead to short bowel (SB) syndrome, resulting in intestinal insufficiency or intestinal failure (IF). Intestinal insufficiency and IF involve deficiency of the proglucagon‐derived hormones glucagon‐like peptide‐1 (GLP‐1) and GLP‐2. Two major problems of SB are epithelial surface loss and accelerated transit. Standard treatment now targets intestinal adaptation with a GLP‐2 analogue to enlarge absorptive surface area. It is possible that additional benefit can be gained from a combination of GLP‐1 and GLP‐2 activity, with the aim to enlarge intestinal surface area and slow intestinal transit. Methods: The GLP‐1– and GLP‐2–specific effects of the novel dual GLP‐1 receptor (GLP‐1R) and GLP‐2 receptor (GLP‐2R) agonist dapiglutide (rINN) were characterized in rodents. Furthermore, in a murine SB model of intestinal insufficiency with 40% ileocecal resection, the influence of dapiglutide on intestinal growth, body weight, food intake, volume status, and stool water content was tested against vehicle and sham‐operated male mice. Results: Dapiglutide significantly improves oral glucose tolerance, reduces intestinal transit time, and promotes intestinal growth. In the SB mouse model, dapiglutide promotes body weight recovery, despite unchanged intake of liquid diet. Dapiglutide promotes significant intestinal growth, as indicated by significantly increased villus height as well as intestinal length. Furthermore, dapiglutide reduces stool water losses, resulting in reduced plasma aldosterone. Conclusion: Dapiglutide possesses specific and potent GLP‐1R and GLP‐2R agonist effects in rodents. In the murine SB model, combined unimolecular GLP‐1R and GLP‐2R stimulation with dapiglutide potently attenuates intestinal insufficiency and potentially also IF.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jpen.2286

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 43

Metadata

Authors
Reiner, J., Berlin, P., Held, J., Thiery, J., Skarbaliene, J., Griffin, J., Russell, W., Eriksson, P., Berner‐Hansen, M., Ehlers, L., Vollmar, B., Jaster, R., Witte, M., & Lamprecht, G.
Venue
Journal of Parenteral and Enteral Nutrition
Publisher
Wiley
Published
2021-11-18
Volume
46
Issue
5
Pages
1107-1118
ISSN
  • 0148-6071 (ISSN-L)
  • 1941-2444
OpenAlex
W3209812207
Cited by
43
References
11
FWCI
3.30
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dapiglutide, a novel dual GLP‐1 and GLP‐2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel. https://app.cochat.ai/papers/10.1002/jpen.2286
The paper
Reiner, J., Berlin, P., Held, J., Thiery, J., Skarbaliene, J., Griffin, J., Russell, W., Eriksson, P., Berner‐Hansen, M., Ehlers, L., Vollmar, B., Jaster, R., Witte, M., & Lamprecht, G. (2022). Dapiglutide, a novel dual GLP‐1 and GLP‐2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel. Journal of Parenteral and Enteral Nutrition. https://doi.org/10.1002/jpen.2286

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.